Lyell Immunopharma
Price & Volume
Stats
See moreOpen | $20.04 |
Previous Close | $20.06 |
Day Range | $20.04-$21.63 |
52W Range | $7.65-$45 |
Market Cap | $449.5M |
Shares Short | 940,269 |
Financials
See moreRevenue (12 Mos) | $36,000 |
Revenue Growth (YoY) | -45.5% |
Gross Profit (12 Mos) | $36,000 |
Diluted EPS | -$16.06 |
News
See moreYahoo Finance • 3 months ago
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Yahoo Finance • 4 months ago
Lyell's Ronde-cel Shows Durable Complete Responses With Manageable Safety In High-Risk LBCL
Yahoo Finance • 4 months ago
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Yahoo Finance • 5 months ago
Lyell Immunopharma buys exclusive global rights to colorectal cancer drug
About
CEO | Dr. Lynn Seely M.D., Ph.D. |
CFO | Ms. Smital Shah M.B.A. |
Address | 201 Haskins Way, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 300 |
